Tissue Factor Pathway Inhibitor (TFPI) Levels in the Plasma and Urine of Children with Meningococcal Disease

Summary

Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of the TF-dependent coagulation system. In meningococcal disease, up-regulation of tissue factor expression on blood monocytes and possibly on endothelial cells has the potential to trigger the activation of the TF-dependent pathway of coagulation. Intravascular coagulation is considered to be a major pathogenic factor in meningococcal disease. We postulated that imbalance between TF expression and TFPI concentration might lead to uncontrolled coagulation in meningococcal disease. The aim of this study was to assess the levels of total TFPI in the plasma of patients with meningococcal disease and assess whether increased leaking of the TFPI was occurring. TFPI antigen levels and activity were measured in the plasma of 54 patients with meningococcal disease, and 13 healthy control children. TFPI antigen level were also determined in the urines of 14 of the 54 and 9 healthy control children. Plasma TFPI activity was reduced in the meningococcal diseased patients (mean of 0.503 ± 0.341 U/ml; control, 1.010 ± 0.199 U/ml; p <0.0001), as was the TFPI antigen levels (mean of 54.85 ± 35.05 ng/ ml; Control, 94.51 ± 11.44 ng/ml; p <0.0001). In contrast, TFPI antigen levels were increased in the urine of these patients when compared to the levels found in the urine of the healthy control children (mean of 12.96 ± 5.392 ng/mmol creatinine; Control, 0.239 ± 0.191 ng/mmol creatinine; p <0.035). A lack of correlation between TFPI-activity and TFPI-antigen plasma levels was observed (r = 0.002, p = 0.85). This data is consistent with the hypothesis that in meningococcal disease there is increased inactivation of plasma TFPI by the up regulation of tissue factor expression but in addition increased clearance of TFPI in urine is occurring.

Keywords

Tissue factor pathway inhibitor - meningococcal disease - glycosaminoglycans - capillary leak

• References

• 1 Jones D. Epidemiology of meningococcal disease in Europe and the USA. In: Meningococcal Disease. Cartwright K. ed. Chichester: John Wiley & Sons Ltd.; 1995: 147-57.
• 2 Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, Lefkowitz L, and Perkins BA. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337: 970-6.
• 3 Osterud B, Flaegstad T. Increased tissue thromboplastine activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49: 5-7.
• 4 Moore KL, Andreoli SP, Esmon N, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-30.
• 5 Broze Jr GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Ann Rev Med 1995; 46: 103-12.
• 6 Weissbach G, Harenberg J, Wendisch J, Pargac N, Thomas K. Tissue factor pathway inhibitor in infants and children. Thromb Res 1994; 73: 41-446.
• 7 Iversen N, Sandset PM, Abildgaard U, Torjesen PA. Binding of tissue factor pathway inhibitor to cultured endothelial cells – influence of glycosaminoglycans. Thromb Res 1996; 84: 267-78.
• 8 Lindhout T, Salemink I, Valentin S, Willems GM. Tissue factor pathway inhibitor: regulation of its inhibitory activity by phospholipid surfaces. Haemostasis 1996; 26: 89-97.
• 9 Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordoy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuos intravenous infusion of heparin in man. Thromb Haemost 1996; 76: 703-9.
• 10 Platt J, Vercellotti GM, Lindman BJ, Oegema TR, Bach FH, Dalmasso AP. Release of heparan sulphate from endothelial cells. J Exp Med 1990; 1363-8.
• 11 Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-34.
• 12 Lindahl U, Hook M. Glycosaminoglycans and their binding to biological macromolecules. Annu Rev Biochem 1978; 47: 385-417.
• 13 Vehaskari VM, Chang CT-C, Stevens JK, Robson AM. The effects of polycations on vascular permeability in the rat. J Clin Invest 1984; 84: 1053-9.
• 14 Levin M. The inflammatory response to infections. In: Infection in the Newborn. de Louvois J, Harvey D. eds. London: John Wiley and Sons Ltd.; 1990: 1-12.
• 15 Klein NJ, Shennan GI, Heyderman RS, Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 1992; 102: 821-32.
• 16 Oragui EE, Nadel S, Kyd P, Levin M. Increased excretion of urinary glycosaminoglycans in meningococcal septicemia and their relationship to proteinuria. Crit Care Med. (in press).
• 17 Baja MS, Rana SV, Wysolmerski RB, Baja SP. Inhibitor of the factor VIIa/ tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-8.
• 18 Brandtzaeg P, Sandset PM, Joo GJ, Ovstebo R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989; 55: 459-70.
• 19 Sandset PM, Roise O, Aasen AO, Abildgaard U. Extrinsic pathway inhibitor in postoperative/posttraumatic septicaemia: increased levels in fatal cases. Haemostasis 1989; 19: 189-95.
• 20 Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-93.
• 21 Sandset PM, Warn-Cramer BJ, Rao VM, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 708-12.
• 22 Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin induced intravascular coagulation and the generalized Schwarzman reaction. Blood 1991; 78: 1496-502.
• 23 Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze GJ, Warren TG, Wun TC. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990; 76: 1538-45.
• 24 Bregengard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coag Fibrinol 1993; 4: 699-706.
• 25 Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997; 89: 4268-74.
• 26 Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and in relation to cholesterol. Blood Coag Fibrinol 1991; 2: 425-33.
• 27 Stephens AC, Rivers RPA. Suppression of human monocyte tissue factor synthesis by antisense oligodeoxynucleotide. Thromb Res 1997; 85: 387-98.
• 28 Bognacki J, Hammelburger J. Functional and immunological methods for the measurement of human tissue factor pathway inhibitor. Blood Coag Fibrinol 1995; 6: S65-S72.
• 29 Pollack MM, Ruttimann UE, Getson PR. Paediatric risk of mortality (PRISM) score. Crit Care Med 1988; 16: 1110-6.
• 30 Sandset PM, Bendz B. Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost 1997; 77: 467-70.
• 31 Hansen JB, Huseby KR, Ezban M, Norday A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor induced coagulation in vitro. Thromb Res 1997; 85: 413-25.